Analgesics in the US

Analgesics in the US

Analgesics in the US is expected to see a slight decline in retail current value terms in 2024. This performance is largely being led by mid-single digit slowdowns for systemic paediatric analgesics, sales of which are still rebounding from the high growth established during 2022’s “tripledemic”, which led sales of paediatric analgesics to skyrocket. In systemic adult analgesics, aspirin and naproxen are expected to continue to witness steadily diminishing value sales, as more consumers are made...

Euromonitor International's Analgesics in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. Forecasts to 2028 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.